Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026

男性/女性性機能障害治療薬の世界市場2016-2026

◆タイトル:Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026
◆商品コード:VGAIN5122114
◆調査・発行会社:visiongain
◆発行日:2015年12月
◆ページ数:156
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、男性/女性性機能障害治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・男性/女性性機能障害治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・男性/女性性機能障害治療薬の世界市場:販売予測
・男性/女性性機能障害治療薬の世界市場:新薬動向
・男性/女性性機能障害治療薬の世界市場:研究開発パイプライン動向
・男性/女性性機能障害治療薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Sexual Dysfunction Drugs – New Study Exploring Potentials of Established and Recently Approved Drugs, Industry Changes and Emerging Opportunities
Are you interested in the future of treatments for sexual disorders? Our new analysis forecasts drug revenues for male and female treatments. There you explore sales results, R&D and opportunities, seeing changing trends and commercial prospects.

Discover, from 2015, progress, opportunities and revenues. Drugs our study covers include treatments for erectile dysfunction (ED), Peyronie’s disease and female hypoactive sexual desire disorder (HSDD). See the effect of recent drug approvals.

Please read on to explore that industry and see what future revenue it could generate.

Predictions and other analysis to benefit your research, plans and decisions
Visiongain’s report gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence.

The future holds promise for pharma companies treating sexual dysfunction. New products enter that market and clinical testing shows commercial potential, especially for HSDD. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2026, our new work shows recent results and market shares. There you find original analysis. You assess research and development too. Also gain 48 tables, 55 charts and two interviews with companies.

Forecasts covering the overall world market and segments for sexual disorder treatments
Discover in our new analysis revenue predictions to 2026 for four drug classes at world level. See what is possible for these submarkets:
• PDE5 inhibitors
• Prostaglandins
• Androgens
• Gonadotrophins
• Other drug classes (grouped).

Our work also divides the overall world market into revenues for male and female treatments.

With our survey you assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors’ actions, technologies and outlooks.

That way you see how those genitourinary medicines develop. You discover where needs and business opportunities exist. With a rising incidence of sexual disorders, the demand for better treatments will continue to enrich the pharmaceutical industry.

Our study also explores sales forecasts by product, showing how those agents can perform. See what gains are possible.

Predictions of leading products’ sales – what is possible for that industry’s top drugs?
How will individual sexual disorder medicines perform from 2015 to 2026 at world level? Our study gives 14 product-level forecasts, including for these brands:
• Cialis
• Viagra
• Gonal-F
• Levitra
• Nebido
• Testim
• Priligy
• Tostran

The report also assesses emerging therapies: Vitaros, Addyi and Xiapex.

With that analysis you hear how high sales can go, finding products and years with highest predicted revenues. You also examine competition. Explore challenges, trends, competitors and opportunities.

Our work also shows you geographical predictions by leading country.

National markets – what outlooks for those sexual medicine revenues?
Our work shows you individual revenue forecasts to 2026 for 11 national markets:
• US
• Japan
• Germany, France, UK, Spain, Italy (EU5)
• Brazil, Russia, India, China (BRIC)
• Rest of world (grouped analysis).

Visiongain forecasts that BRIC countries will show the fastest growth and account for 17% of the overall world market by 2026. The rise of that region’s sales will be driven, in particular, by revenues in China and India.

The recent FDA approval of Addyi (flibanserin), for hypoactive sexual desire disorder, gives a breakthrough for female sexual dysfunction treatment. Suppliers of therapies will take encouragement from that development serving a large, emerging need.

Our report also shows trends leading to novel and improved treatments, forces changing that market.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Sexual Dysfunctions Treatment
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Sexual Dysfunctions and Treatment Options
2.1 Diagnosis – ICD-10 and DSM-V
2.2 Male Sexual Dysfunctions
2.2.1 Sexual Desire Dysfunctions
2.2.2 Erectile Dysfunction
2.2.3 Priapism
2.2.4 Peyronie’s Disease
2.2.5 Premature Ejaculation
2.2.6 Hypogonadism
2.3 Female Sexual Dysfunctions
2.3.1 Dysfunctions of Arousal
2.3.2 Persistent Sexual Arousal Syndrome
2.3.3 Dysfunctions of Orgasm
2.3.4 Sexual Pain Dysfunctions
2.3.4.1 Dyspareunia
2.3.4.2 Vaginismus
2.3.5 Vulvodynia

3. The World Sexual Dysfunctions Drugs Market, 2015-2026
3.1 Global Sexual Dysfunctions Drugs Forecast 2015-2026
3.2 Sexual Dysfunction Drugs Market by Drug Class
3.2.1 PDE5 Inhibitors – Still Hold the Biggest Market Share
3.2.2 Prostaglandins – Dominated by Alprostadils
3.2.3 Androgens – Will New Delivery Technology Drive This Submarket?
3.2.4 Gonadotrophins – New Products Launched Expected
3.2.5 Other Drug Classes Market – Will See Significant Growth
3.3 Sexual Dysfunctions Drugs Market by Gender
3.3.1 Male Sexual Dysfunctions Drugs Market 2015-2026 – Declining as Originator Drugs Lose Patent Protection
3.3.2 Female Sexual Dysfunctions Drugs Market 2015-2026 – a Developing Market Holding Promising Commercial Potential

4. Sexual Dysfunction-Treating Drugs: Revenue Forecasts, 2015-2026
4.1 Cialis (Eli Lilly) – Faces Patent Expiry
4.2 Viagra (Pfizer) – Will Extended Patent in the US Protect Revenue?
4.3 Gonal-F (Merck KGaA) – Slow Growth in the First Half of the Forecast Period
4.4 Puregon (Merck & Co.) – Expected to Decline Significantly
4.5 Decapeptyl SR (Ipsen Ltd) – Growing Until the End of the First Half of the Forecast Period
4.6 Caverject Dual Chamber (Pfizer) – Growing During the First Half of the Forecast Period
4.7 Levitra (Bayer) – Sales Eroded by Cheaper PDE5 Inhibitors?
4.8 Nebido (Bayer) – Intramuscular Formulation of Testosterone Undecanoate
4.9 Testim (Ferring Pharmaceuticals) – Differentiated by Consistent Transdermal Absorption
4.10 Priligy (J&J/A. Menarini Pharma UK SRL) – SSRI to Treat Premature Ejaculation
4.11 Stendra/Spedra (VIVUS/Endo/Auxilium Pharmaceuticals) – Newest PDE5 Inhibitor
4.12 MUSE (Meda Pharmaceuticals) – Suppository Prostaglandin
4.13 Viridal Duo/Edex (UCB Pharma/Auxilium Pharmaceuticals) – Growing Strongly in the First Half of the Forecast Period
4.14 Tostran (ProStrakan Pharmaceuticals) – Eroded by Generic Competition Since 2014
4.15 Vitaros (Takeda) – Topical Formulation of Alprostadil
4.16 Restandol Testocaps (Merck & Co.) – Testosterone Replacement
4.17 Sustanon 250 (Aspen Pharma Trading) – Preferred Testosterone Replacement in the UK
4.18 Bemfola (Finox Biotech UK & Ireland Ltd.) – Biosimilar
4.19 Menopur (Ferring Pharmaceuticals) – a Preparation of Gonadotrophins
4.20 Pregnyl (Merck & Co.) – to Treat Hypogonadism
4.21 Androcur (Bayer Plc) – to Treat Androgen-related Conditions
4.22 Gonapeptyl (Ferring Pharmaceuticals) – Depot Injection
4.23 Intrinsa (Procter & Gamble) – Testosterone Patch

5. Emerging Therapies for Sexual Disorders
5.1 Vitaros (Takeda) – Topical Cream to Treat Erectile Dysfunction
5.2 Addyi (Sprout/Valeant Pharmaceuticals) – First Approved Drug for Female Sexual Dysfunction
5.3 Xiapex (Auxilium Pharmaceuticals)- First Approved Drug for Peyronie’s Disease

6. Leading Companies in the Sexual Dysfunction Drugs Market
6.1 Eli Lilly – Leading With Cialis
6.2 Pfizer – Will It Overtake Eli Lilly in This Forecast Period?
6.3 Merck KGaA – Driven by Sales in Emerging Markets
6.4 Merck & Co. – Will It Soon Lose Its Share to Competitors?
6.5 Ipsen Ltd – Ongoing Clinical Trials for Decapeptyl May Drive Further Growth
6.6 Bayer – Orodispersible Form of Levitra Not Pushing Revenue?

7. Leading National Markets: Revenue Forecasts, 2015-2026
7.1. The US Sexual Dysfunctions Drugs Market, 2015-2026 – Leader of the Pack
7.2. The Japanese Sexual Dysfunctions Drugs Market, 2015-2026 – Still Driven by Viagra and Cialis Sales
7.3 EU5 Sexual Dysfunctions Drugs Market, 2015-2026 – Cost Containment Will Slow the Market
7.4 BRIC Sexual Dysfunctions Drugs Market, 2015-2026 – Driven by Growth in China and India
7.5 Other Regions’ Sexual Dysfunctions Drugs Market, 2015-2026 – Expected High Growth Rate

8. R&D Pipelines for Sexual Dysfunctions Treatment
8.1 R&D Pipeline Drugs for Male Sexual Dysfunctions – Still Dominated by ED
8.1.1 Tissue Genesis Cell Isolation System (Tissue Genesis, Inc.) – ED
8.1.2 Adipose-Derived Stem Cell Injection (Ageless Regenerative Institute) – ED
8.1.3 Selegiline (University of South Florida) – ED
8.1.4 VL#FIA3-30 (VasoLead) – ED
8.1.5 MED2002 (Futura Medical) – ED
8.1.6 MED2005 (Futura Medical Developments Ltd) – ED
8.1.7 Fispemifene (NexMed) – ED and Secondary Hypogonadism
8.1.8 Transdermal Androgel (Johns Hopkins University) – Priapism
8.1.9 Adipose Tissue Stem Cell Injection (Man Clinic for Andrology, Male Infertility and Sexual Dysfunction) – Peyronie’s Disease
8.1.10 AA4500 and ErecAid Esteem Manual Vacuum Therapy System (Endo Pharmaceuticals) – Peyronie’s Disease
8.1.11 H-22411(Allergan) – Peyronie’s Disease
8.1.12 AA4500 (Allergan) – Peyronie’s Disease
8.1.13 IX-01 (Ixchelsis Limited) – Premature Ejaculation
8.1.14 CDFR0812-15 (CTC Bio, Inc.) – Premature Ejaculation
8.2 R&D Pipeline Drugs for Female Sexual Dysfunctions – Emerging Therapies
8.2.1 Tribulus Terrestris – Female Hypoactive Sexual Desire Disorder
8.2.2 Bremelanotide (Palatin Technologies) – Female Hypoactive Sexual Desire Disorder
8.2.3 Lybridos (Emotional Brain NY Inc.) – Female Hypoactive Sexual Desire Disorder
8.2.4 Lorexys (S1 Biopharma) – Female Hypoactive Sexual Desire Disorder
8.2.5 SST-6007 (Strategic Science & Technologies, LLC) – Female Hypoactive Sexual Desire Disorder
8.2.6 TBS-2 (Acerus Pharmaceuticals Corporation) – Orgasmic Disorder
8.2.7 SST-6006 (Strategic Science & Technologies, LLC) – Female Sexual Dysfunction
8.2.8 Fluocinonide Cream (OHSU Knight Cancer Institute National Cancer Institute (NCI)) – Painful Sexual Intercourse

9. Qualitative Analysis of the Sexual Dysfunctions Drugs Market 2015-2026
9.1 SWOT Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
9.1.1 Strengths
9.1.2 Weaknesses
9.1.3 Opportunities
9.1.4 Threats
9.2 STEP Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
9.2.1 Social
9.2.2 Technological
9.2.3 Economic
9.2.4 Political

10. Research Interviews from Our Survey – 2015
10.1 Dr. Carl Spana and Mr. Stephen Wills, Palatin Technologies
10.1.1 Palatin Technologies, Inc.
10.1.2 Female Sexual Dysfunction Market – What Are the Challenges?
10.1.3 Industry Effort to Bridge the Gaps
10.1.4 Drivers and Restraints of the FSD Market
10.1.5 Bremelanotide – On-Demand Treatment for HSDD
10.1.6 Designing Clinical Trials to Assess Drugs for FSDs – Remains a Challenge?
10.1.7 Commercial Potential of Bremelanotide
10.2 James Barder, CEO, Futura Medical
10.2.1 Futura Medical
10.2.2 Will the ED Treatment Market Show Growth?
10.2.3 Unmet Needs of ED Treatment and Management
10.2.4 MED2002 for ED – Targeted Delivery
10.2.5 DermaSys – Improves Permeation of APIs through the Skin
10.2.6 DermaSys –Therapeutic Benefits to Other Therapeutic Areas?
10.2.7 MED2002 – Could Potentially Meet the Unmet Demand in ED

11. Conclusions
11.1 Male Sexual Dysfunction Drugs Market
11.2 Female Sexual Dysfunction Drugs Market
11.3 Leading National Markets
11.4 Drugs in the Pipeline

List of Tables
Table 1.1 Global Sexual Dysfunction Drugs Market: Regional and National Submarket Revenue Forecasts ($bn), 2015-2026
Table 3.1 Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.2 Global Sexual Dysfunction Drugs Market Revenue by Drug Class: Forecasts ($bn), 2015-2026
Table 3.3 Global PDE5 Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.4 Global Prostaglandins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.5 Global Androgens Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.6 Global Gonadotrophins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.7 Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.8 Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Shares (%), 2015-2026
Table 3.9 Global Sexual Dysfunction Drugs Market Revenue by Gender: Forecasts ($bn), 2015-2026
Table 3.10 Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.11 Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 3.12 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
Table 4.1 Leading Sexual Dysfunction Drugs by Revenue ($bn), 2014
Table 4.2 Cialis Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.3 Viagra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.4 Gonal-F Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.5 Puregon Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.6 Decapeptyl Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.7 Caverject Dual Chamber Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.8 Levitra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.9 Nebido Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.10 Testim Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.11 Priligy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.12 Stendra/Spedra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.13 MUSE Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.14 Viridal Duo/Edex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.15 Tostran Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.16 Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026
Table 6.1 Top Companies for Sexual Dysfunction Drugs: Revenues ($bn) and Market Shares (%), 2014
Table 6.2 Eli Lilly– Revenue ($bn) and Share (%), 2014
Table 6.3 Pfizer– Revenue ($bn) and Share (%), 2014
Table 6.4 Merck KGaA– Revenue ($bn) and Share (%), 2014
Table 6.5 Merck & Co. – Revenue ($bn) and Share (%), 2014
Table 6.6 Ipsen Ltd – Revenue ($bn) and Share (%), 2014
Table 6.7 Bayer – Revenue ($bn) and Share (%), 2014
Table 7.1 Global Sexual Dysfunction Drugs Market: National Submarket Revenue Forecasts ($bn), 2015-2026
Table 7.2 Grouped Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026
Table 7.3 US Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.4 Japanese Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.5 EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.6 BRIC Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.7 Other Regions’ Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 8.1 List of Selected Drug Candidates for Male Sexual Dysfunctions
Table 8.2 List of Selected Drug Candidates for Female Sexual Dysfunctions
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Sexual Dysfunction Drugs Market, 2015
Table 9.2 Social, Technological, Economic and Political Analysis of the Sexual Dysfunction Drugs Market, 2015
Table 11.1 Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Share (%) by Product Category, 2014, 2020, 2026
Table 11.2 Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Shares (%) by Region, 2014, 2020, 2026

List of Figures
Figure 3.1 The Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 3.2 Global PDE5 Market: Revenue Forecast ($bn), 2015-2026
Figure 3.3 Global Prostaglandins Market: Revenue Forecast ($bn), 2015-2026
Figure 3.4 Global Androgens Market: Revenue Forecast ($bn), 2015-2026
Figure 3.5 Global Gonadotrophins Market: Revenue Forecast ($bn), 2015-2026
Figure 3.6 Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), 2015-2026
Figure 3.7 Global Sexual Dysfunction Drugs Market by Drug Class: Revenue Forecasts ($bn), 2015-2026
Figure 3.8 Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Share (%), 2015-2026
Figure 3.9 Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 3.10 Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 3.11 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
Figure 3.12 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
Figure 3.13 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
Figure 3.14 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
Figure 3.15 Global Sexual Dysfunction Drugs Market: Submarket Forecasts ($bn), 2015-2026
Figure 4.1 Cialis Revenue Forecast ($bn), 2015-2026
Figure 4.2 Viagra Revenue Forecast ($bn), 2015-2026
Figure 4.3 Gonal-F Revenue Forecast ($bn), 2015-2026
Figure 4.4 Puregon Market Forecast ($bn), 2015-2026
Figure 4.5 Decapeptyl Market Forecast ($bn), 2015-2026
Figure 4.6 Caverject Dual Chamber Market Forecast ($bn), 2015-2026
Figure 4.7 Levitra Revenue Forecast ($bn), 2015-2026
Figure 4.8 Nebido Revenue Forecast ($bn), 2015-2026
Figure 4.9 Testim Revenue Forecast ($bn), 2015-2026
Figure 4.10 Priligy Revenue Forecast ($bn), 2015-2026
Figure 4.11 Stendra/Spedra Market Forecast ($bn), 2015-2026
Figure 4.12 MUSE Revenue Forecast ($bn), 2015-2026
Figure 4.13 Viridal Duo/Edex Revenue Forecast ($bn), 2015-2026
Figure 4.14 Tostran Revenue Forecast ($bn), 2015-2026
Figure 4.15 Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026
Figure 6.1 Top Producers of Sexual Dysfunction Drugs: Market Shares (%), 2014
Figure 6.2 Eli Lilly’s Drugs by Share of Company Revenue (%), 2014
Figure 6.3 Pfizer’s Drugs by Share of Company Revenue (%), 2014
Figure 6.4 Merck KGaA’s Drugs by Share of Company Revenue (%), 2014
Figure 6.5 Merck & Co.’s Drugs by Share of Company Revenue (%), 2014
Figure 6.6 Ipsen Ltd.’s Drugs by Share of Company Revenue (%), 2014
Figure 6.7 Bayer’s Drugs by Share of Company Revenue (%), 2014
Figure 7.1 Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026
Figure 7.2 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
Figure 7.3 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
Figure 7.4 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
Figure 7.5 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014-2026
Figure 7.6 US Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 7.7 Japanese Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 7.8 EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), 2015-2026
Figure 7.9 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
Figure 7.10 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
Figure 7.11 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
Figure 7.12 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
Figure 7.13 BRIC Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
Figure 7.14 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
Figure 7.15 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
Figure 7.16 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
Figure 7.17 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
Figure 7.18 Other Regions’ Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026

【レポートのキーワード】

性機能障害治療薬、性機能不全治療、医薬品、製薬

★調査レポート[男性/女性性機能障害治療薬の世界市場2016-2026] ( Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026 / VGAIN5122114) 販売に関する免責事項
[男性/女性性機能障害治療薬の世界市場2016-2026] ( Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026 / VGAIN5122114) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆